Nimodip

✅ Active Ingredient Overview Table:

🌿 What is Nimodipine 30 mg (Nimodip)?

Nimodip is a dihydropyridine calcium channel blocker with high lipophilicity, allowing selective cerebral vessel penetration. It is used primarily to prevent and reduce the severity of cerebral vasospasm following subarachnoid hemorrhage (SAH). By inhibiting calcium influx in vascular smooth muscle, Nimodipine promotes vasodilation and improves cerebral blood flow.

Clinical studies demonstrate that Nimodipine 30 mg administered every 4 hours for 21 days reduces neurological deficits and mortality in SAH patients. Early initiation within 96 hours of hemorrhage onset maximizes benefit.

For detailed prescribing and safety information, consult the FDA label for Nimotop and the Drugs.com monograph. Additional guidance is available via the NHS Medicines A–Z entry and the WHO Essential Medicines List.

🧬 Pharmacology & Mechanism of Action

Nimodipine’s cerebral selectivity arises from its high lipid solubility and preferential binding to cerebral arteries.

💡 Indications & Dosing

Administer on an empty stomach for optimal absorption; avoid concomitant grapefruit products.

⚠️ Precautions & Side Effects

Common Adverse Effects:

• Hypotension, dizziness
• Headache, flushing

Serious (rare):

• Severe hypotension leading to ischemia
• Reflex tachycardia
• GI upset

Monitor blood pressure closely, especially in elderly or volume-depleted patients. Delay dose if systolic BP <90 mmHg.

🏥 Storage Instructions

Store Nimodip at 20–25°C in original blister pack. Protect from moisture and light. Keep out of reach of children.

🌐 Availability & Purchasing

• USA: Prescription-only (Nimotop); limited availability.
• UK & EU: Prescription required; Nimodipine generics available.
• Australia: Prescription and TGA approval needed.

Importing from India may reduce costs; ensure regulatory compliance and valid prescription.

🔗 Related Cerebrovascular Therapies

• Verapamil
• Tranexamic Acid – antifibrinolytic.

🎥 Educational Video on Nimodipine

👨‍⚕️ Expert Insight: Dr. Anil Gupta, Neurocritical Care Specialist

“Nimodipine remains the standard for SAH management to prevent cerebral vasospasm. Timely initiation and hemodynamic monitoring are crucial to maximize outcomes.”